COMPANY
History
logo
2021

11.A License for the Management of Human cells etc. was Granted by MFDS

10.HIEstem (IVH) SIT is Approved by MFDS through changing the clinical protocol for HIEstem (HIE)

05.HIEstem for HIE is Designated as one of 'Orphan Drugs in Development Stage' from MFDS, No.2021-192

04.Registration of 2nd R&D Center (Seoul, South Korea)

03.Establishment of IP-R&D plan for HIEstem Designated as a National Project
(100 million KRW)

2020

11.Series B Funding (paid-in capital of 13 billion KRW)

07.Commercialization of Pipelines is Designated as a National Project
(800 million KRW)

06.GMP facility ‘M-Plant’ is Established
(Seoul, South Korea)

04.HIEstem is Designated as a National Project
(1.5 billion KRW)

02.Phase I Clinical trial on HIEstem for HIE Started

01.MOU is signed with IPscent for Commercialization of Pipelines

2019

12.ahNSCs for SCI, as a Neurospine designated as National Project (150 million KRW)

07.Series A Funding (paid-in capital of 8 billion KRW)

06.HIEstem (HIE) SIT is Approved by MFDS

02.HIEstem (HIE) IIT is Approved by MFDS (a.k.a. KFDA)

2018

07.Seed Funding (paid-in capital of 2 billion KRW)

05.Registration of R&D Center (Suwon, South Korea)

03.MEDINNO Inc. is Established (Seoul, South Korea)

맨위로